Silence Therapeutics Plc American Depository Share Cash Flow Statement
NASDAQ: SLNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Silence Therapeutics Plc American Depository Share free cash flow
In fiscal 2025, Silence Therapeutics Plc American Depository Share generated -$62.3 million of operating cash flow and spent $55,000 on capital expenditures. That left free cash flow of -$62.3 million, a free-cash-flow margin of -11149.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Silence Therapeutics Plc American Depository Share cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 |
|---|---|---|---|---|
| Net Income | -88.61M | -45.31M | -54.23M | -50.33M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 312.00K | 336.00K | 369.00K | 379.00K |
| Stock-Based Compensation | 8.07M | 16.31M | 16.27M | 12.69M |
| Change in Working Capital | 690.00K | -29.69M | -9.93M | -6.17M |
| Operating Cash Flow | -62.27M | -67.64M | -49.46M | -57.04M |
| Capital Expenditures | -55.00K | -211.00K | -56.00K | -173.00K |
| Investing Cash Flow | -47.99M | -21.97M | 19.29M | -20.50M |
| Financing Cash Flow | 15.00K | 142.09M | 31.94M | 52.58M |
| Net Change in Cash | -110.25M | 52.48M | 1.77M | -24.96M |
| Free Cash Flow | -62.33M | -67.85M | -49.52M | -57.22M |
This table shows 4 annual periods of Silence Therapeutics Plc American Depository Share's cash flow statement, from FY 2025 back to FY 2022, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SLN's reporting calendar. What is a cash flow statement?